Supplementary Written Evidence Submitted by TranspariMED
ABOUT THE SUBMITTING PARTY
TranspariMED is a UK-based initiative working to promote clinical trial transparency through a combination of research, advocacy and facilitating peer-to-peer capacity building.
Note: TranspariMED jointly with Cochrane and the Transparency International Global Health Programme already submitted evidence to this inquiry in September 2021. The present submission is being made by TranspariMED alone, with the purpose of updating the Committee on recent salient research.
NEW STUDY SHOWS LINK BETWEEN SANCTIONS AND CLINICAL TRIAL REPORTING
The U.S. Food and Drug Administration has recently (re-)started sending out letters to companies and institutions that have failed to make their clinical trial results public as required by law. The letters warn companies and institutions that they could face a fine of $10,000 per day for each day a clinical trial result is not made public.
These letters have been highly successful at driving legal compliance. A study published in JAMA on 12 November 2021 found that over 90% of missing trial results flagged in regulatory warning letters had been made public at the time of assessment, highlighting the effectiveness of even the threat of sanctions.
EVIDENCE OF WIDER IMPACT OF SANCTIONS
The U.S. Food and Drug Administration’s enforcement efforts are reportedly having impact far beyond the clinical trials singled out for enforcement action:
At present, the evidence for these wider impacts is only anecdotal. No relevant peer-reviewed studies have yet been published.